López Pablo, De Jesús Omayra, Yamamura Yasuhiro, Rodríguez Nayra, Arias Andrea, Sánchez Raphael, Rodríguez Yadira, Tamayo-Agrait Vivian, Cuevas Wilfredo, Rivera-Amill Vanessa
1 AIDS Research Program, Ponce Health Sciences University-School of Medicine , Ponce Research Institute, Ponce, Puerto Rico .
2 Puerto Rico Community Network for Clinical Research on AIDS, University of Puerto Rico , Medical Sciences Campus, San Juan, Puerto Rico .
AIDS Res Hum Retroviruses. 2018 Jun;34(6):507-516. doi: 10.1089/AID.2017.0305. Epub 2018 May 23.
HIV-1 subtype B virus is the most prevalent subtype in Puerto Rico (PR), accounting for about 90% of infection in the island. Recently, other subtypes and circulating recombinant forms (CRFs), including F(12_BF), A (01_BF), and CRF-39 BF-like, have been identified. The purpose of this study is to assess the distribution of drug resistance mutations and subtypes in PR. A total of 846 nucleotide sequences from the period comprising 2013 through 2017 were obtained from our "HIV Genotyping" test file. Phylogenetic and molecular epidemiology analyses were performed to evaluate the evolutionary dynamics and prevalence of drug resistance mutations. According to our results, we detected a decrease in the prevalence of protease inhibitor, nucleoside reverse transcriptase inhibitor (NRTI), and non-NRTI (NNRTI) resistance mutations over time. In addition, we also detected recombinant forms and, for the first time, identified subtypes C, D, and CRF-24BG in PR. Recent studies suggest that non-subtypes B are associated with a high risk of treatment failure and disease progression. The constant monitoring of viral evolution and drug resistance mutation dynamics is important to establish appropriate efforts for controlling viral expansion.
HIV-1 B亚型病毒是波多黎各(PR)最流行的亚型,约占该岛感染病例的90%。最近,还发现了其他亚型和流行重组形式(CRF),包括F(12_BF)、A (01_BF)和CRF-39 BF样毒株。本研究的目的是评估波多黎各耐药突变和亚型的分布情况。从我们的“HIV基因分型”测试文件中获取了2013年至2017年期间的总共846个核苷酸序列。进行了系统发育和分子流行病学分析,以评估耐药突变的进化动态和流行情况。根据我们的结果,我们检测到蛋白酶抑制剂、核苷类逆转录酶抑制剂(NRTI)和非核苷类逆转录酶抑制剂(NNRTI)耐药突变的流行率随时间下降。此外,我们还检测到了重组形式,并且首次在波多黎各鉴定出C、D亚型和CRF-24BG。最近的研究表明,非B亚型与治疗失败和疾病进展的高风险相关。持续监测病毒进化和耐药突变动态对于制定控制病毒传播的适当措施很重要。